Despite bumpy launches for two of its key generics in the US – rivals to Amarin’s Vascepa (icosapent ethyl) and GlaxoSmithKline’s Advair (fluticasone/salmeterol) – and the pressures of the COVID-19 pandemic, Hikma has nevertheless managed to deliver solid growth in 2020, with a double-digit ramp-up in operating profit outpacing a 6% turnover increase on the back of solid performances across its three key business segments.
Hikma’s overall turnover for 2020 grew by 6%, both as reported and in constant-currency terms, to $2.341bn, while the firm’s...
